LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Inexpensive Multipurpose Point-of-Care Analyzer Unveiled at 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 29 Jul 2015
An inexpensive point-of-care (POC) instrument capable of performing multiple clinical laboratory blood tests was unveiled at the 2015 AACC Annual Meeting & Clinical Lab Expo (Atlanta, GA, USA).

Investigators from DiaSys Diagnostics India (Mumbai, India) unveiled their new QDx InstaLab POC blood chemistry device. This instrument combines inexpensive microfluidic cartridge technology with novel nanomaterial-based plastic electrochemical biosensors.

The QDx InstaLab can perform all of the clinical tests that are routinely ordered as part of a yearly physical exam to evaluate organ function and check for conditions such as diabetes, liver disease, and kidney disease. Furthermore, the instrument can determine cholesterol levels and screen for bleeding problems.

The instrument was designed to perform these tests using samples comprising a few drops of blood from a finger prick. Results are available in three to 10 minutes or less.

“In areas where cost and efficiency are of paramount importance, labs will be able to consolidate all instrumentation into a single QDx InstaLab,” said Dr. Vijaywanth Mathur, head of research and development at DiaSys Diagnostics India. “This breakthrough technology will revolutionize and enable quality healthcare for all in low to middle income and high income countries, and particularly in rural, semirural, second tier, and third tier cities where there is no access to healthcare diagnostics or the cost per test is so high.”

Related Links:

2015 AACC Annual Meeting & Clinical Lab Expo
DiaSys Diagnostics India


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)

Channels

Molecular Diagnostics

view channel
Image Credit: Adobe Stock

AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026

Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more